SK Bioscience Co (XKRX:302440) Debt-to-Revenue : 0.63 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is SK Bioscience Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

SK Bioscience Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩6,957 Mil. SK Bioscience Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩385,857 Mil. SK Bioscience Co's annualized Revenue for the quarter that ended in Dec. 2024 was ₩627,397 Mil. SK Bioscience Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.63.

SK Bioscience Co Debt-to-Revenue Historical Data

The historical data trend for SK Bioscience Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Debt-to-Revenue Chart

SK Bioscience Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Revenue

Get a 7-Day Free Trial

0.54

0.11

0.25

0.06

1.47

SK Bioscience Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial															0.06	1.13	0.93	0.83	0.63

Competitive Comparison of SK Bioscience Co's Debt-to-Revenue

For the Biotechnology subindustry, SK Bioscience Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SK Bioscience Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SK Bioscience Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where SK Bioscience Co's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

SK Bioscience Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

SK Bioscience Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(6956.508	+	385857.239)	/	267545.049
	=	1.47

SK Bioscience Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(6956.508	+	385857.239)	/	627396.9
	=	0.63

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

SK Bioscience Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of SK Bioscience Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

SK Bioscience Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbioscience.co.kr

SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co Headlines

No Headlines